(Q38573810)

4 September 2017

title

Psychopharmacological Agents and Suicide Risk Reduction: Ketamine and Other Approaches (English)

1 reference

4 September 2017

0 references

0 references

Rayan K Al Jurdi

1

1 reference

4 September 2017

Alan Swann

series ordinal

2

1 reference

4 September 2017

Sanjay J Mathew

series ordinal

3

1 reference

4 September 2017

language of work or name

English

0 references

publication date

1 October 2015

1 reference

Current Psychiatry Reports

4 September 2017

published in

1 reference

4 September 2017

volume

17

1 reference

4 September 2017

issue

10

1 reference

4 September 2017

page(s)

81

1 reference

Leading causes of unintentional and intentional injury mortality: United States, 2000-2009.

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Cognitive therapy for the prevention of suicide attempts: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Two-Year Randomized Controlled Trial and Follow-up of Dialectical Behavior Therapy vs Therapy by Experts for Suicidal Behaviors and Borderline Personality Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Suicidal risk during treatment with clozapine: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Antidepressants and suicidal behaviour in unipolar depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Fluoxetine in borderline personality disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Fluoxetine in the treatment of borderline and schizotypal personality disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

The role of ECT in suicide prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Properties of the interaction between ketamine and opiate binding sites in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Properties of the optical isomers and metabolites of ketamine on the high affinity transport and catabolism of monoamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Consciousness and anesthesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

(R,S)-Ketamine metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Antidepressant effects of ketamine in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Rapid response with ketamine on suicidal cognition in resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Oral ketamine augmentation for chronic suicidality in treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Urgent ketamine infusion rapidly eliminated suicidal ideation for a patient with major depressive disorder: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Peripheral serotonergic markers in acutely suicidal patients. 1. Comparison of serotonergic platelet measures between suicidal individuals, nonsuicidal patients with major depression and healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

The concentration of neurotransmitter metabolites in the cerebrospinal fluid of suicidal individuals: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

The dexamethasone suppression test as a predictor of suicidal behavior in unipolar depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

The dexamethasone suppression test and suicide prediction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Suicide risk in hepatitis C and during interferon-alpha therapy: a review and clinical update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Severe depression, suicide attempts, and ideation during the use of interferon beta by patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Elevated cytokine expression in the orbitofrontal cortex of victims of suicide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Connecting inflammation with glutamate agonism in suicidality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Ketamine and peripheral inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Ketamine inhibits tumor necrosis factor-alpha and interleukin-6 gene expressions in lipopolysaccharide-stimulated macrophages through suppression of toll-like receptor 4-mediated c-Jun N-terminal kinase phosphorylation and activator protein-1 activa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Signal-transducing mechanisms of ketamine-caused inhibition of interleukin-1 beta gene expression in lipopolysaccharide-stimulated murine macrophage-like Raw 264.7 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Mental health: A road map for suicide research and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Suicidal behavior disorder as a diagnostic entity in the DSM-5 classification system: advantages outweigh limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Benefits and burdens of placebos in psychiatric research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Protection of human subjects in intervention research for suicidal behavior.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0614-9

Practice guideline for the assessment and treatment of patients with suicidal behaviors

21 January 2018

1 reference

12 December 2020

Tryptophan kynurenine metabolism as a common mediator of genetic and environmental impacts in major depressive disorder: the serotonin hypothesis revisited 40 years later

1 reference

12 December 2020

Fluoxetine: no association with suicidality in obsessive-compulsive disorder

1 reference

12 December 2020

The relationship between fluoxetine use and suicidal behavior in 654 subjects with anxiety disorders

1 reference

12 December 2020

Reduced suicide risk during lithium maintenance treatment

1 reference

12 December 2020

Generalisability of results from randomised drug trials. A trial on antimanic treatment

1 reference

12 December 2020

Fluoxetine treatment of impulsive aggression in DSM-III-R personality disorder patients

1 reference

12 December 2020

A preliminary trial of fluoxetine in refractory borderline patients.

1 reference

12 December 2020

Antidepressants and suicidal behavior: cause or cure?

1 reference

12 December 2020

Studies of CSF 5-HIAA in depression and suicidal behaviour

1 reference

12 December 2020

Arguments for the specificity of the antisuicidal effect of lithium.

1 reference

12 December 2020

Psychosocial and pharmacological treatments for deliberate self harm

1 reference

12 December 2020

Suicide Risk in Placebo vs Active Treatment in Placebo-Controlled Trials for Schizophrenia

1 reference

12 December 2020

Pharmacotherapy of suicidal behaviour in major depression, schizophrenia and bipolar disorder

1 reference

12 December 2020

Platelet and whole blood serotonin content in depressed inpatients: correlations with acute and life-time psychopathology

1 reference

12 December 2020

Psychometric changes as well as analgesic action and cardiovascular adverse effects of ketamine racemate versus s-(+)-ketamine in subanesthetic doses

1 reference

12 December 2020

Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms

1 reference

12 December 2020

Lack of association between fluoxetine and suicidality in bulimia nervosa

1 reference

12 December 2020

Deaths: final data for 2008.

1 reference

12 December 2020

Ketamine suppresses proinflammatory cytokine production in human whole blood in vitro.

1 reference

12 December 2020

A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report

1 reference

12 December 2020

10.1007/S11920-015-0614-9

Identifiers

DOI

1 reference

Dimensions Publication ID

4 September 2017

1044291743

0 references

1 reference